Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...
On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...
A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...
Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it ...
Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...
Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...
The addition of Monjuvi to standard-of-care therapy reduced the risk of disease progression, relapse, or death in patients ...
Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.
The following is a summary of “Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma,” published in the December 2024 issue of Hematology by ...
Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate ...
Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and ...